ArticleBlood2012
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 89 citations in OpenAlex.
- Dual IRE1 targets: Determinants of the cell fate?The FEBS journal · 2026Review
- Regulatory Mechanisms of XBP1 in Tumorigenesis and Cancer Progression: Challenges and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.Nature communications · 2026Article
- Transcription factor XBP1s promotes endometritis-induced epithelial-mesenchymal transition by targeting MAP3K2, a key gene in the MAPK/ERK pathway.Cell communication and signaling : CCS · 2025Article
- IRE1α pathway: A potential bone metabolism mediator.Cell proliferation · 2024Review
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma.Haematologica · 2024Article
- Article
- The Role of XBP1 in bone metabolism.Frontiers in endocrinology · 2023Review
- Increased BMSC exosomal miR-140-3p alleviates bone degradation and promotes bone restoration by targeting Plxnb1 in diabetic rats.Journal of nanobiotechnology · 2022Article
- The Role of Galectin-3 in 1α,25(OH)Veterinary sciences · 2021Article
- A novel XBP1 variant is highly enriched in cancer tissues and is specifically required for cancer cell survival.Biochemical and biophysical research communications · 2021Article
- COX2 confers bone marrow stromal cells to promoting TNFα/TNFR1β-mediated myeloma cell growth and adhesion.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation.Stem cell research & therapy · 2020Article
- Endoplasmic Reticulum Stress in Bone Metastases.Frontiers in oncology · 2020Review
- Expression of XBP1s in peritoneal mesothelial cells is critical for inflammation-induced peritoneal fibrosis.Scientific reports · 2019Article
- Proteostasis In The Endoplasmic Reticulum: Road to Cure.Cancers · 2019Review
- Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s.JCI insight · 2019Article
- Unravel the molecular mechanism of XBP1 in regulating the biology of cancer cells.Journal of Cancer · 2019Review
- New agents in the Treatment of Myeloma Bone Disease.Calcified tissue international · 2018Review
- The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
BM stromal cells (BMSCs) are key players in the microenvironmental support of multiple myeloma (MM) cell growth and bone destruction. A spliced form of the X-box-binding protein-1 (XBP1s), a major proximal effector of unfolded protein response signaling, is highly expressed in MM cells and plays an indispensable role in MM pathogenesis. In the present study, we found that XBP1s is induced in the BMSCs of the MM microenvironment. XBP1s overexpression in healthy human BMSCs enhanced gene and/or protein expression of VCAM-1, IL-6, and receptor activator of NF-κB ligand (RANKL), enhancing BMSC support of MM cell growth and osteoclast formation in vitro and in vivo. Conversely, deficiency of XBP1 in healthy donor BMSCs displayed a range of effects on BMSCs that were opposite to those cells with overexpression of XBP1s. Knock-down of XBP1 in MM patient BMSCs greatly compromised their increased VCAM-1 protein expression and IL-6 and RANKL secretion in response to TNFα and reversed their enhanced support of MM-cell growth and osteoclast formation. Our results demonstrate that XBP1s is a pathogenic factor underlying BMSC support of MM cell growth and osteoclast formation and therefore represents a therapeutic target for MM bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.